These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 38004264)

  • 1. Prolactin in Polycystic Ovary Syndrome: Metabolic Effects and Therapeutic Prospects.
    Mastnak L; Herman R; Ferjan S; Janež A; Jensterle M
    Life (Basel); 2023 Oct; 13(11):. PubMed ID: 38004264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolactin secretion in polycystic ovary syndrome (PCOS).
    Szosland K; Pawlowicz P; Lewiński A
    Neuro Endocrinol Lett; 2015; 36(1):53-8. PubMed ID: 25789595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What is the optimal prolactin cutoff for predicting the presence of a pituitary adenoma in patients with polycystic ovary syndrome?
    Kim SI; Yoon JH; Park DC; Yang SH; Kim YI
    Int J Med Sci; 2023; 20(4):463-467. PubMed ID: 37057215
    [No Abstract]   [Full Text] [Related]  

  • 4. The value of prolactin in predicting prolactinοma in hyperprolactinaemic polycystic ovarian syndrome.
    Kyritsi EM; Dimitriadis GK; Angelousi A; Mehta H; Shad A; Mytilinaiou M; Kaltsas G; Randeva HS
    Eur J Clin Invest; 2018 Jul; 48(7):e12961. PubMed ID: 29845629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. To what extent does polycystic ovary syndrome influence the cut-off value of prolactin? Findings of a community-based study.
    Mahboobifard F; Rahmati M; Amiri M; Azizi F; Ramezani Tehrani F
    Adv Med Sci; 2022 Mar; 67(1):79-86. PubMed ID: 34998115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypothalamic dopaminergic tone and prolactin bioactivity in women with polycystic ovary syndrome.
    Hernández I; Parra A; Méndez I; Cabrera V; Cravioto MC; Mercado M; Díaz-Sánchez V; Larrea F
    Arch Med Res; 2000; 31(2):216-22. PubMed ID: 10880731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polycystic ovary syndrome and hyperprolactinemia are distinct entities.
    Filho RB; Domingues L; Naves L; Ferraz E; Alves A; Casulari LA
    Gynecol Endocrinol; 2007 May; 23(5):267-72. PubMed ID: 17558684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Association Between Prolactin and Metabolic Parameters in PCOS Women: A Retrospective Analysis.
    Yang H; Di J; Pan J; Yu R; Teng Y; Cai Z; Deng X
    Front Endocrinol (Lausanne); 2020; 11():263. PubMed ID: 32477263
    [No Abstract]   [Full Text] [Related]  

  • 9. Prolactin Is Associated With Insulin Resistance and Beta-Cell Dysfunction in Infertile Women With Polycystic Ovary Syndrome.
    Yang H; Lin J; Li H; Liu Z; Chen X; Chen Q
    Front Endocrinol (Lausanne); 2021; 12():571229. PubMed ID: 33716958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Prevalence of Polycystic Ovary Syndrome, Its Phenotypes and Cardio-Metabolic Features in a Community Sample of Iranian Population: Tehran Lipid and Glucose Study.
    Farhadi-Azar M; Behboudi-Gandevani S; Rahmati M; Mahboobifard F; Khalili Pouya E; Ramezani Tehrani F; Azizi F
    Front Endocrinol (Lausanne); 2022; 13():825528. PubMed ID: 35299965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum metabolomics profiling by proton nuclear magnetic resonance spectrometry of the response to single oral macronutrient challenges in women with polycystic ovary syndrome (PCOS) compared with male and female controls.
    Escobar-Morreale HF; Martínez-García MÁ; Insenser M; Cañellas N; Correig X; Luque-Ramírez M
    Biol Sex Differ; 2023 Sep; 14(1):62. PubMed ID: 37736753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of common risk factors between polycystic ovary syndrome and Alzheimer's disease: a narrative review.
    Sarahian N; Sarvazad H; Sajadi E; Rahnejat N; Eskandari Roozbahani N
    Reprod Health; 2021 Jul; 18(1):156. PubMed ID: 34311759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies.
    Sanchez-Garrido MA; Tena-Sempere M
    Mol Metab; 2020 May; 35():100937. PubMed ID: 32244180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME - PART 2.
    Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
    Endocr Pract; 2015 Dec; 21(12):1415-26. PubMed ID: 26642102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thiazolidinediones for the therapeutic management of polycystic ovary syndrome : impact on metabolic and reproductive abnormalities.
    Elkind-Hirsch KE
    Treat Endocrinol; 2006; 5(3):171-87. PubMed ID: 16677059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of hyperprolactinemia upon clinical symptoms of patients with polycystic ovary syndrome].
    Wang Y; Hu ZP; Li MZ; Li R; Wang LN; Chen XN; Yang CS; Qiao J
    Zhonghua Yi Xue Za Zhi; 2009 Oct; 89(37):2599-603. PubMed ID: 20137674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miRNAs as a novel clinical biomarker and therapeutic targets in polycystic ovary syndrome (PCOS): A review.
    Abdalla M; Deshmukh H; Atkin SL; Sathyapalan T
    Life Sci; 2020 Oct; 259():118174. PubMed ID: 32745529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between circulating neuregulin 4 levels and metabolic, aterogenic, and AMH profile of polycystic ovary syndrome.
    Kurek Eken M; Sahin Ersoy G; Yayla Abide C; Sanverdi İ; Devranoglu B; Kutlu T; Çevik Ö
    J Obstet Gynaecol; 2019 Oct; 39(7):975-980. PubMed ID: 31064233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing.
    Chang PL; Lindheim SR; Lowre C; Ferin M; Gonzalez F; Berglund L; Carmina E; Sauer MV; Lobo RA
    J Clin Endocrinol Metab; 2000 Mar; 85(3):995-1000. PubMed ID: 10720029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-polycystic ovary syndrome and polymenorrhoea as new facets of polycystic ovary syndrome (PCOS): Evidences from a single centre data set.
    Ganie MA; Rashid A; Baba MS; Zargar MA; Wani IA; Nisar S; Wani IA; Douhath S; Sriwastawa M; Geer MI; Asrar MM; Kutum R; Hassan S; Khan S; Rafi W; Bhat DA; Showkat W; Sahar T; Choh NA; Khurshid R; Mudassar S; Shah ZA; Shabir I; Sofi SA; Gupta N; Hafeez I; Sreenivas V
    Clin Endocrinol (Oxf); 2023 Dec; 99(6):566-578. PubMed ID: 37656656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.